Latest News
Otsuka Wins Approval for Novel Rare Kidney Drug
Otsuka Gains Approval for First of Its Kind Treatment Against Rare Kidney Disease In a significant milestone for kidney disease care, Otsuka Pharmaceutical has received accelerated approval from the US Food and Drug Administration for a new therapy for Immunoglobulin...
Latest News
ALS- Clinical Signals of a “Synaptic Regenerative” Approach!
Pharmaceutical approaches to ALS remain sparse and "hard-to-develop". Riluzole (approved 1995) and edaravone (IV in 2017, oral in 2022) only offer modest benefits. More recently, Biogen's Qalsody (tofersen) was approved for SOD1-mutant ALS. But a new wave of new...
Decision Frameworks in Pharma
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine What Works, What Kills What, and Why It Matters In pharmaceutical R&D, where billions ride on the flip of a biological coin, decision frameworks aren’t just nice-to-haves - they’re...
Follow the Science? It Would Rather Follow a Leader… (2025 Update)
Eight years on from the first version of this article, “follow the science” is still the industry’s favourite comfort blanket. It sounds noble, unassailable, the kind of thing you put on a lab-wall poster next to a photo of Rosalind Franklin. (Following the X...
Durvalumab approved in the US
Durvalumab approved in the US as first & only perioperative immunotherapy for patients with early gastric & gastroesophageal cancers! The FDA approved Durvalumab (Imfinzi) in combination with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
First Malaria Treatment Approved for Babies and Young Children
A landmark milestone in global health has been reached as the antimalarial drug Coartem Baby has received approval from the Swiss regulator Swissmedic. It is the first treatment specifically designed for newborns and very young infants suffering from malaria. Bridging...
ProImmune Introduces ProVE SL Monomers to Boost T Cell Research
ProImmune has launched its new ProVE SL (Self-Loading) MHC Class I monomers, positioning these reagents as a next-generation tool for researchers studying antigen-specific CD8+ T cells. The announcement highlights the company’s aim to accelerate T cell research by...
Novo Nordisk Locks Horns with Pfizer in Late Bid for Metsera
Danish pharmaceutical leader Novo Nordisk has made a dramatic late entry into the takeover race for United States biotech Metsera, challenging Pfizer’s earlier agreement and sparking a fierce bidding war in one of the most competitive areas of the life sciences...
Chinese Biotech Industry Shows No Signs of Slowing
The Chinese biotechnology sector continues to accelerate, signing high-value deals and expanding its global footprint even as the United States prepares new restrictions on collaborations and funding. Despite growing geopolitical tensions, China’s biopharma industry...
AI and Early Detection of Dementia: Advancing Life Science Frontiers
Dementia continues to pose a significant challenge in neuroscience and clinical care, affecting millions worldwide. Early detection is pivotal in slowing disease progression and implementing preventive interventions. Life sciences are increasingly leveraging...
UK Life Sciences Growth Spreads Beyond London, Oxford and Cambridge
London, Oxford and Cambridge have long been the heartlands of the UK life sciences sector, but other regions across the country are now rapidly emerging as centres of innovation. The Midlands, the North of England, Scotland and Northern Ireland are developing strong...
How the UK May Be Undervaluing Life Sciences Manufacturing Investments
Concerns are mounting that the United Kingdom’s official appraisal framework is systematically underestimating the economic and social value of investments in life sciences manufacturing. Industry bodies and independent analysts warn that the methods used to evaluate...
AI Giants Nvidia, Microsoft and Google Drive Innovation in Pharma R&D
The intersection of artificial intelligence (AI) and pharmaceutical research is transforming drug discovery, clinical trials, and healthcare innovation. Leading technology companies Nvidia, Microsoft, and Google are spearheading this evolution, applying advanced AI...
Emerging Drug Therapies in the Fight Against Sarcopenia
Why Sarcopenia Matters Sarcopenia, the age-related decline in skeletal muscle mass and strength, has become a growing concern in ageing populations. The condition contributes significantly to frailty, falls, fractures, disability and even mortality, placing an...
Trump’s Proposed Drug Tariff Could Reshape the UK Pharma Landscape
It is unusual for trade policy in the United States to have such a direct impact on the UK life sciences sector, but President Donald Trump’s proposed 100 per cent tariff on branded and patented pharmaceuticals could do just that. If enacted, the measure would impose...
Sustainable and Green Manufacturing Practices in the Life Sciences Industry
The life sciences sector is undergoing a significant transformation as it embraces sustainable and green manufacturing practices. These initiatives aim to reduce environmental impact, enhance operational efficiency, and meet the growing demand for eco-friendly...
Claude for Life Sciences – Major AI Pivot into Drug Discovery and Research
Artificial intelligence company Anthropic is making a significant move into the life sciences sector with the launch of Claude for Life Sciences, a version of its Claude language model platform tailored for scientific research, drug discovery and regulatory workflows....
First Malaria Treatment Approved for Babies and Young Children
A landmark milestone in global health has been reached as the antimalarial drug Coartem Baby has received approval from the Swiss regulator Swissmedic. It is the first treatment specifically designed for newborns and very young infants suffering from malaria. Bridging...
ProImmune Introduces ProVE SL Monomers to Boost T Cell Research
ProImmune has launched its new ProVE SL (Self-Loading) MHC Class I monomers, positioning these reagents as a next-generation tool for researchers studying antigen-specific CD8+ T cells. The announcement highlights the company’s aim to accelerate T cell research by...
Novo Nordisk Locks Horns with Pfizer in Late Bid for Metsera
Danish pharmaceutical leader Novo Nordisk has made a dramatic late entry into the takeover race for United States biotech Metsera, challenging Pfizer’s earlier agreement and sparking a fierce bidding war in one of the most competitive areas of the life sciences...
Chinese Biotech Industry Shows No Signs of Slowing
The Chinese biotechnology sector continues to accelerate, signing high-value deals and expanding its global footprint even as the United States prepares new restrictions on collaborations and funding. Despite growing geopolitical tensions, China’s biopharma industry...
AI and Early Detection of Dementia: Advancing Life Science Frontiers
Dementia continues to pose a significant challenge in neuroscience and clinical care, affecting millions worldwide. Early detection is pivotal in slowing disease progression and implementing preventive interventions. Life sciences are increasingly leveraging...
UK Life Sciences Growth Spreads Beyond London, Oxford and Cambridge
London, Oxford and Cambridge have long been the heartlands of the UK life sciences sector, but other regions across the country are now rapidly emerging as centres of innovation. The Midlands, the North of England, Scotland and Northern Ireland are developing strong...
How the UK May Be Undervaluing Life Sciences Manufacturing Investments
Concerns are mounting that the United Kingdom’s official appraisal framework is systematically underestimating the economic and social value of investments in life sciences manufacturing. Industry bodies and independent analysts warn that the methods used to evaluate...
AI Giants Nvidia, Microsoft and Google Drive Innovation in Pharma R&D
The intersection of artificial intelligence (AI) and pharmaceutical research is transforming drug discovery, clinical trials, and healthcare innovation. Leading technology companies Nvidia, Microsoft, and Google are spearheading this evolution, applying advanced AI...
Emerging Drug Therapies in the Fight Against Sarcopenia
Why Sarcopenia Matters Sarcopenia, the age-related decline in skeletal muscle mass and strength, has become a growing concern in ageing populations. The condition contributes significantly to frailty, falls, fractures, disability and even mortality, placing an...
Trump’s Proposed Drug Tariff Could Reshape the UK Pharma Landscape
It is unusual for trade policy in the United States to have such a direct impact on the UK life sciences sector, but President Donald Trump’s proposed 100 per cent tariff on branded and patented pharmaceuticals could do just that. If enacted, the measure would impose...
Sustainable and Green Manufacturing Practices in the Life Sciences Industry
The life sciences sector is undergoing a significant transformation as it embraces sustainable and green manufacturing practices. These initiatives aim to reduce environmental impact, enhance operational efficiency, and meet the growing demand for eco-friendly...
Claude for Life Sciences – Major AI Pivot into Drug Discovery and Research
Artificial intelligence company Anthropic is making a significant move into the life sciences sector with the launch of Claude for Life Sciences, a version of its Claude language model platform tailored for scientific research, drug discovery and regulatory workflows....
Featured Articles
Further News
Genentech Cuts 87 Jobs in Latest Round of Layoffs at South San Francisco HQ
Genentech has carried out another round of workforce reductions, cutting 87 positions at its South San Francisco headquarters. The layoffs, filed last week and set to take effect on September 15, were disclosed in a California Worker Adjustment and Retraining...
Navigating Life with Haemophilia with Pfizer
Life with haemophilia can be challenging but advances in science are helping people with haemophilia to lead active and fulfilling lives. What is Haemophilia? Haemophilia is a family of rare genetic blood disorders caused by a clotting factor deficiency, which...
Microsoft’s Copilot Set to License Harvard Medical School Content
Microsoft is reportedly preparing a major update to its Copilot AI assistant that will let it draw on licensed medical content from Harvard Health Publishing when responding to user queries about healthcare. The development signals a strategic shift toward embedding...
Merck Abandons £1bn UK Expansion, Citing Insufficient Government Support
US pharmaceutical heavyweight Merck has decided to halt its planned £1 billion expansion in the UK, criticising the government for a lack of substantial investment in the life sciences sector. The company, which operates under the name MSD in Europe, announced it will...
Hyperfine Banks on $17.5 Million Public Stock Offering
Medical imaging company Hyperfine, listed on the Nasdaq as HYPR, has announced the pricing of an underwritten public offering of 14 million shares of its Class A common stock at $1.25 per share, yielding gross proceeds of approximately $17.5 million before...
UK Crown Estate Buys Harwell East, Opening 4.5m sq ft for Science & Innovation
The Crown Estate has completed the acquisition of Harwell East, a 221 acre site adjacent to the Harwell Science and Innovation Campus in Oxfordshire. The development could deliver up to 4.5 million square feet of laboratory, research, manufacturing and office space,...
Amazon to Launch Prescription Kiosks in LA One Medical Clinics
Amazon is gearing up to roll out prescription kiosks inside One Medical clinics in Los Angeles beginning December 2025. These in office machines will allow patients to collect common prescription medications such as antibiotics, inhalers, and treatments for high blood...
Astatine-211: The Alpha-Emitter Gaining Momentum in Targeted Radiotherapy
Astatine, the heaviest halogen and the rarest naturally occurring element, has long been a scientific curiosity. Among its many isotopes, ²¹¹At has emerged over the past decade as a frontrunner in the quest to harness alpha particles for highly targeted radiotherapy....
Blood Test for 50+ Cancers Shows Promise in Faster Diagnosis
A new multi cancer blood test developed by the United States biotechnology company Grail has demonstrated in North America the ability to detect a wide range of cancers, including many for which no screening programmes exist, at an early and potentially treatable...
Eli Lilly Expands U.S. Manufacturing with Multi-Billion Investment
Eli Lilly & Company is doubling down on U.S. investment, unveiling a series of ambitious plans to expand its domestic pharmaceutical manufacturing infrastructure. These efforts come amid mounting political pressure to reshore drug production and rising competition...
Trump’s Recent Guidance on Tylenol, Vaccines, and Children Draws Fire from Medical Community
In late September 2025, former U.S. President Donald J. Trump revived a series of controversial health claims and policy proposals concerning women especially pregnant women and children, triggering sharp pushback from medical experts, public health authorities, and...
7,000 Steps a Day May Improve Brain and Reduce Disease Risk
Walking around 7,000 steps each day could help sharpen cognition and shield against a variety of chronic illnesses, according to a major new analysis. This target may be more attainable, yet still effective, than the widely publicised 10,000 step goal. Published in...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
US Scientists Create Human Embryos from Skin Cells
In a ground breaking advance in reproductive biology, researchers in the United States have for the first time created early-stage human embryos by converting DNA from skin cells into functional eggs and then fertilising them with sperm. Though still at an...
MHRA and NICE Pilot Aligned Pathway for Faster Patient Access
A Coordinated Effort to Accelerate Approvals The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) have launched a new initiative inviting early adopters to trial an accelerated and aligned...
Stem Cell Breakthrough: Woman Reverses Type 1 Diabetes Using Her Own Cells
In a pioneering medical achievement, a 25-year-old woman in China has become the first person in the world to reverse Type 1 diabetes using stem cells derived from her own body. The groundbreaking study, published in Cell in September 2024, marks a turning point in...
FDA Panel Rebuffs GSK’s Bid to Relaunch Blenrep Over Eye Toxicity Concerns
A panel of independent experts convened by the U.S. Food and Drug Administration (FDA) has recommended against approving GSK’s (GSK.L) blood cancer treatment Blenrep, citing concerns over known ocular side effects. The decision prompted a nearly 5% drop in the British...
NHS Leads Global Rollout of Groundbreaking ‘Trojan Horse’ Blood Cancer Treatment
The NHS in England is leading the world as the first healthcare system to introduce a pioneering ‘trojan horse’ therapy for patients with blood cancer, offering the potential to delay disease progression nearly three times longer than current treatment options....
FDA Picks George Tidmarsh as Head of Drug Regulation Division
The Food and Drug Administration commissioner, Marty Makary, has selected George Tidmarsh, a former biotech executive and Stanford-affiliated pediatrician, to lead the agency’s drug regulatory arm, according to a source familiar with the matter. The appointment of...
The Dawn of a New Era: World’s First mRNA Lung Cancer Vaccine Enters Global Clinical Trials
In a historic stride toward personalised cancer treatment, BioNTech—the German biotech giant behind one of the first COVID-19 mRNA vaccines—has launched the world’s first mRNA-based lung cancer vaccine, BNT116, into Phase I clinical trials across seven countries. This...
Genentech Cuts 87 Jobs in Latest Round of Layoffs at South San Francisco HQ
Genentech has carried out another round of workforce reductions, cutting 87 positions at its South San Francisco headquarters. The layoffs, filed last week and set to take effect on September 15, were disclosed in a California Worker Adjustment and Retraining...
Navigating Life with Haemophilia with Pfizer
Life with haemophilia can be challenging but advances in science are helping people with haemophilia to lead active and fulfilling lives. What is Haemophilia? Haemophilia is a family of rare genetic blood disorders caused by a clotting factor deficiency, which...
Microsoft’s Copilot Set to License Harvard Medical School Content
Microsoft is reportedly preparing a major update to its Copilot AI assistant that will let it draw on licensed medical content from Harvard Health Publishing when responding to user queries about healthcare. The development signals a strategic shift toward embedding...
Merck Abandons £1bn UK Expansion, Citing Insufficient Government Support
US pharmaceutical heavyweight Merck has decided to halt its planned £1 billion expansion in the UK, criticising the government for a lack of substantial investment in the life sciences sector. The company, which operates under the name MSD in Europe, announced it will...
Hyperfine Banks on $17.5 Million Public Stock Offering
Medical imaging company Hyperfine, listed on the Nasdaq as HYPR, has announced the pricing of an underwritten public offering of 14 million shares of its Class A common stock at $1.25 per share, yielding gross proceeds of approximately $17.5 million before...
UK Crown Estate Buys Harwell East, Opening 4.5m sq ft for Science & Innovation
The Crown Estate has completed the acquisition of Harwell East, a 221 acre site adjacent to the Harwell Science and Innovation Campus in Oxfordshire. The development could deliver up to 4.5 million square feet of laboratory, research, manufacturing and office space,...
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.